VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Immune tolerance induction (ITI) is a treatment for hemophilia patients with inhibitors, achieving success in approximately 75% of high responders.
• Selecting the appropriate coagulation factor concentrate for ITI remains a challenge.
• Emerging evidence suggests plasma-derived products rich in von Willebrand factor (VWF) may enhance ITI efficacy.

Purpose of the Study:

• To evaluate the role of VWF/FVIII products in immune tolerance induction.
• To initiate two prospective studies, RESIST(exp) and RESIST(naïve), to further investigate ITI strategies.
• To assess ITI success in patients with prior treatment failures and in treatment-naïve high-risk patients.

Main Methods:

• Review of retrospective data from Germany and France, and a prospective cohort study.
• Planned prospective studies include an observational trial (RESIST(exp)) for patients with prior ITI failure using VWF-free FVIII concentrates.
• A randomized, controlled trial (RESIST(naïve)) for high-risk, ITI-naïve patients.

Main Results:

• Retrospective and prospective data indicate a high success rate when using VWF/FVIII products for ITI.
• These findings support the potential benefit of VWF-containing products in ITI.

Conclusions:

• VWF/FVIII products demonstrate promise for improving immune tolerance induction outcomes in hemophilia patients.
• The RESIST(exp) and RESIST(naïve) studies will provide further critical data on ITI efficacy and product selection.